US FDA approves supplemental new drug application for licence extension of Eucrisa (crisaborole) ointment 2% in children aged 3 months and above with mild-to-moderate atopic dermatitis (AD)

Crisaborole ointment 2% was previously approved for use in adults and children 2 years of age and older in the US. This ointment was recommended for EU approval by CHMP earlier this year, for mild-to-moderate AD in adults and children from 2 years of age only.


Biospace Inc.